Robert J Chilton

Author PubWeight™ 10.13‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2010 1.12
2 PROactive: time for a critical appraisal. Eur Heart J 2008 1.11
3 Applications of miRNA technology for atherosclerosis. Curr Atheroscler Rep 2014 0.84
4 Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets 2013 0.84
5 Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 2003 0.84
6 Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich) 2005 0.84
7 Left ventricular remodeling: one small step for the extracellular matrix will translate to a giant leap for the myocardium. Congest Heart Fail 2013 0.80
8 A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities. J Clin Hypertens (Greenwich) 2013 0.79
9 Diabetic endovascular disease: role of coronary artery revascularization. Am J Cardiol 2006 0.78
10 Is isolated systolic hypertension worse than combined systolic/diastolic hypertension? J Clin Hypertens (Greenwich) 2012 0.78
11 Heart rate reduction: an old and novel candidate heart failure therapy. Hypertension 2012 0.77
12 Tumor necrosis factor-alpha--converting enzyme roles in hypertension-induced hypertrophy: look both ways when crossing the street. Hypertension 2009 0.75
13 Other important applications for beta-blockers in high-risk patients. Postgrad Med 2003 0.75
14 Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations. Postgrad Med 2011 0.75